Calidi Biotherapeutics, Inc. (NYSE American: CLDI), a clinical-stage biotechnology company specializing in innovative immunotherapies, has concluded a $3.9 million fundraising initiative. This funding was achieved through a registered direct offering and a concurrent private placement with a single institutional investor.
The transaction involved the sale of 3,325,000 shares of Calidi’s common stock at $0.65 per share and pre-funded warrants for an additional 2,728,000 shares at $0.649 per warrant. In the private placement, the company issued Series G common warrants to purchase up to 6,053,000 shares of common stock. The Series G warrants are priced at $0.6954 per share, exercisable six months post-issuance, and will remain valid for seven and a half years.
The gross proceeds from the combined offerings totaled approximately $3.9 million before deducting placement agent fees and other expenses. Ladenburg Thalmann & Co. Inc. acted as the exclusive placement agent for the transactions.
Calidi plans to allocate the net proceeds to working capital, general corporate purposes, and advancing its preclinical and clinical programs. The company’s proprietary platforms focus on developing stem cell-based delivery systems that enhance the efficacy of oncolytic viruses for treating high-grade gliomas and solid tumors.
The registered direct offering was conducted under an effective shelf registration statement filed with the U.S. Securities and Exchange Commission (SEC). Meanwhile, the Series G warrants issued in the private placement were offered under exemptions from SEC registration requirements.
Headquartered in San Diego, Calidi Biotherapeutics is pioneering immuno-oncology solutions designed to harness the immune system to combat cancer. Its platforms utilize allogeneic stem cells to deliver oncolytic viruses directly to tumors, amplifying therapeutic effects while improving patient safety. These approaches aim to address both high-grade gliomas and disseminated solid tumors.
By securing this funding, Calidi is positioned to advance its mission of developing transformative cancer therapies that could potentially improve outcomes for patients battling aggressive malignancies.
